New hope for amyloidosis patients facing organ transplants

31 January 2012

Amyloidosis patients are expected to see some significant breakthroughs in treatment over the next three years, reducing side effects and possibly the need for organ transplants, research by health care market analysis specialist GlobalData has found.

Amyloidosis occurs when a build-up of proteins forms an abnormally folded structure within the body's cells and tissues, which then forms an insoluble deposit in a particular organ. Although amyloidosis is a severe and life-threatening disease, the market currently lacks an approved therapy.

Sector forecast to grow to $2.58 billion by 2019

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology